Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Massachusetts, Boston

About this trial

The primary goal of this study is to see if photodynamic therapy (PDT) is effective for treatment of lesions in the oral cavity which have high risk of becoming oral cancer. PDT treatment uses a drug, called a photosensitizer, which makes the diseased cells become light-sensitive such that they are destroyed when laser light is delivered to the target lesion. In this study a new handheld device, called SITOS (a "Screen, Image and Treat Optical System), is used. The ability of this device to simultaneously visualize the inside of the mouth and deliver laser light to the target site will be evaluated. The main questions this study seeks to answer are:

* Can this treatment completely cure oral potentially malignant lesions (OPML) without need for surgery? * Do lesions recur after PDT treatment? * Is the SITOS device easy to use for the doctor and comfortable for the patient, both as an oral imaging device and as a treatment device?

Eligibility criteria

Qualifiers

Willing and available for follow-up for at least one year and at prerequisite time intervals.

All patients above the age of 18 years and willing to voluntarily give a signed informed consent.

Karnofsky Performance Score above 80 or ECOG 0 or 1.

The subjects meeting the following laboratory eligibility criteria during a time not older than 2 months before accrual

Disqualifiers

Hypersensitivity against active substances and porphyrins.

Known diagnosis of porphyria.

Simultaneous use of other potentially phototoxic substances (eg; tetracyclines, sulphonamides, fluoroquinolones, hypericin extracts).

Uncontrolled concurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled cardiac and renal diseases or psychiatric illness.

Trial design

Treatments tested in this trial

  • 5-Amino Levulinic Acid

Treatment groups

65 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Massachusetts, Boston

Lead sponsor

Massachusetts General Hospital

Collaborator

University of Arizona

Collaborator

Aligarh Muslim University

Collaborator

Karkinos Healthcare Hospitals Ernakulam, Kerala, India

Collaborator

National Cancer Institute (NCI)

Collaborator